Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Pain Management|January 18, 2020
Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancerBruce H Chamberlain, Michelle Rhiner, Neal E Slatkin, et al.
Pain Practice : the Official Journal of World Institute of Pain|November 19, 2016
Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer PainRichard Rauck, Neal E Slatkin, Nancy Stambler, et al.
Magnetic Resonance Imaging|November 1, 1989
Correlation between liver iron content and magnetic resonance imaging in ratsJ Israel, E Unger, K Buetow, et al.
Journal of Pain Research|August 3, 2023
Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial DoseBruce H Chamberlain, Michelle Rhiner, Neal E Slatkin, et al.
Immunology|December 1, 1996
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRnE J Israel, D F Wilsker, K C Hayes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 25, 2021
The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studiesDarren M Brenner, Neal E Slatkin, Nancy Stambler, et al.
Gastroenterology|November 1, 1990
Prevention of necrotizing enterocolitis in the rat with prenatal cortisoneE J Israel, E J Schiffrin, E A Carter, et al.
Chemmedchem|November 25, 2025
Structure-Property Associations: Breaking Paradigms for Linking Chemical Structures and Biological Properties in Drug DiscoveryEdgar López-López, J Israel Espinoza-Castañeda, Karina Martinez-Mayorga, et al.
BMJ Quality Improvement Reports|August 26, 2016
Improving Clinical Remission Rates in Pediatric Inflammatory Bowel Disease with Previsit PlanningJeffrey R Savarino, Jess L Kaplan, Harland S Winter, et al.
Digestive Diseases and Sciences|June 8, 2017
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic SensitivityM Pimentel, B D Cash, A Lembo, et al.
Pageof 14